Related Experiment Video
Updated: Jun 25, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary
Insights
Optimal timing for 600 mg clopidogrel pre-treatment in stable coronary artery disease (CAD) patients before PCI was studied. Maximal antiplatelet efficacy was achieved 1 day after administration, influenced by baseline platelet reactivity.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Optimal timing for 600 mg clopidogrel pre-treatment before percutaneous coronary intervention (PCI) in stable coronary artery disease (CAD) patients remains unestablished by randomized trials.
- This study investigated the time course of platelet inhibition following clopidogrel loading in this patient population.
Discussion:
- Platelet inhibition with 600 mg clopidogrel demonstrated significant suppression for up to 4 days.
- Maximal inhibition of platelet activation occurred at 28 hours post-administration, with two-thirds of patients achieving a Platelet Reactivity Index (PRI) below 50%.
Key Insights:
- Maximal antiplatelet efficacy of 600 mg clopidogrel in stable CAD patients is achieved approximately 1 day after administration.
- Baseline platelet reactivity significantly influences the time course and extent of clopidogrel's antiplatelet effect.
- A strong correlation exists between baseline PRI and PRI values at 28 hours, and between 12 and 28 hours post-administration.
Outlook:
- Further research may explore personalized clopidogrel dosing strategies based on individual baseline platelet reactivity.
- Understanding the kinetics of clopidogrel's antiplatelet effect can inform clinical decisions regarding PCI timing and dual antiplatelet therapy duration.
- This study provides crucial data for optimizing pre-procedural antiplatelet management in stable CAD patients.
Background:
The optimal timing for 600 mg clopidogrel pre-treatment before planned PCI in patients with stable coronary artery disease has never been tested in a randomized trial.
Methods:
The time course of platelet inhibition was investigated in 105 patients pre-treated with clopidogrel ≥ 6 h before the planned procedure. Flow cytometric analysis of the vasodilator stimulated phosphoprotein (VASP) phosphorylation state was done and a Platelet Reactivity Index (PRI) was calculated prior to treatment (baseline) and at 12, 28, 36, 60, 84 and 108 h after the clopidogrel loading dose administration.
Results:
The maximal inhibition of platelet activation was seen at 28 h post administration (PRI mean 36 ± 23%), and 2/3 of patients had PRI value <50%. At 12 h 47% of patients had PRI value ≥ 50% (mean 45±21%). 600 mg of clopidogrel significantly suppressed platelet activation for 4 days. A correlation was between baseline PRI and its values by 28 h (r(S)=0.48, p<0.001), between 12 h-28 h the correlation was strong (r(S)=0.77, p<0.001).
Conclusion:
The time curve of clopidogrel efficacy was dependent on baseline platelet reactivity. Among stable CAD patients, pre-treatment with 600 mg of clopidogrel resulted in maximal antiplatelet efficacy 1 day after drug administration.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses